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Abstract
The mechanistic/mammalian target of rapamycin complex 1 (mTORC1) plays a pivotal role in the regulation of
skeletal muscle protein synthesis. Activation of the complex leads to phosphorylation of two important sets of
substrates, namely eIF4E binding proteins and ribosomal S6 kinases. Phosphorylation of these substrates then leads to
an increase in protein synthesis, mainly by enhancing translation initiation. mTORC1 activity is regulated by several
inputs, such as growth factors, energy status, amino acids and mechanical stimuli. Research in this field is rapidly
evolving and unraveling how these inputs regulate the complex. Therefore this review attempts to provide a brief and
up-to-date narrative on the regulation of this marvelous protein complex. Additionally, some sports supplements
which have been shown to regulate mTORC1 activity are discussed.
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Background
The mechanistic/mammalian target of rapamycin com-
plex 1 (mTORC1) has emerged as a key factor in reg-
ulation of skeletal muscle protein synthesis (MPS) [1].
mTORC1 is a protein complex comprised of the three core
subunits mTOR, Raptor and mLST8 [2] and is regulated
by several inputs, such as growth factors, energy status,
amino acids and mechanical stimuli. mTOR forms the
catalytic center of the two signaling complexes mTORC1
and mTORC2 [3], of which the first is primarily involved
in regulation of MPS. Activation of the complex leads to
phosphorylation of its two important sets of substrates
which are involved in the translation of mRNA to pro-
tein. One comprising the eukaryotic initiation factor 4E
(eIF4E)-binding proteins 4E-BP1 and 2. 4E-BPs inhibit the
formation of the eIF4F complex which facilitates recruit-
ment of the small (40S) ribosomal subunit to the 5’ end
of mRNA [4]. Therefore, 4E-BPs inhibit mRNA transla-
tion initiation and phosphorylation by mTORC1 relieves
this inhibition. The other important set of substrates of
mTORC1 comprise the ribosomal S6 kinases S6K1 and
2. Phosphorylation of the S6Ks by mTORC1 activates
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them and resultingly modulates functions of translation
initiation factors [5]. Additionally, S6Ks are thought to
promote ribosome biogenesis and thereby increasing the
translational capacity of the cell [6].
This manuscript attempts to provide a brief and up-to-
date narrative of some important factors which regulate
mTORC1 activity at the cellular level. Additionally, some
sports supplements which have been shown to regulate
mTORC1 activity are discussed.
Regulation by growth factors
Research examining the regulation of mTORC1 by growth
factors has mainly focused on the effect of insulin and
insulin-like growth factor-1. The insulin receptor (IR)
and insulin-like growth factor-1 receptor (IGF-1R) both
belong to the class of tyrosine kinase receptors. Activation
of either receptor leads to phosphorylation of the insulin
receptor substrates (IRS) proteins. This, in turn, exposes
binding sites on these proteins which enable interaction
with other proteins which contain a Src Homology 2
(SH2) domain. Among the SH2 domain-containing pro-
teins is phosphatidylinositol-3-kinase (PI3K). IRS acti-
vates PI3K by associating with the SH2 domain of the
kinase [7]. Activated PI3K then phosphorylates inosi-
tol phospholipids embedded in the plasma membrane
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on a hydroxyl group located at carbon 3. This gives
rise to phosphoinositides, such as phosphatidylinositol
(3,4,5)-triphosphate (PIP3). PIP3 interacts with Pleck-
strin homology (PH) domain-containing proteins, thereby
recruiting these to the plasma membrane. Two important
PH domain-containing proteins are 3-phosphoinositide
dependent protein kinase (PDK1) and Akt. The inter-
action of PIP3 with Akt enhances phosphorylation (and
thereby activation) of the latter. Additionally, interaction
of PIP3 with PDK1 leads to phosphorylation of Akt by
PDK1 (Fig. 1).
Akt is considered an important upstream regulator of
mTORC1 [8]. The Akt family of proteins comprises the
three isoforms Akt1, Akt2 and Akt3. Akt1 and Akt2
are expressed in skeletal muscle, while Akt3 is not [9].
PDK1 phosphorylates Akt1 and Akt2 at residues Thr308
and Thr309, respectively. However, full Akt kinase activ-
ity also requires phosphorylation at a serine residue
[10, 11], Ser473 and Ser473 on Akt1 and Akt2, respec-
tively. The Rictor-containing mTOR complex mTORC2
is possibly the kinase responsible for phosphorylation
of the serine residue [12]. Mechanistic studies com-
monly measure the phosphorylation status of Akt1 at
residues Thr308 and Ser473 in order to assess Akt
activity.
Myostatin, a potent negative regulator of skeletal muscle
growth [13], has also been found to regulate Akt phos-
phorylation [14]. Myostatin is a member of the transform-
ing growth factor-β superfamily and a ligand for activin
type II receptors (ActRIIA and ActRIIB). After binding
to its receptor, it phosphorylates and activates activin
type I receptors [15]. These receptors then phosphorylate
and activate the transcription factors Smad2 and Smad3
which then form a heterotrimeric complex by joining with
Smad4. After formation, the complex can translocate to
the nucleus where it regulates several key genes involved
in skeletal muscle growth. Knockout of myostatin in ani-
mal models has been found to dramatically increase skele-
tal muscle fiber size and number [16–18]. In postnatal
skeletal muscle, inhibition of myostatin signaling mainly
affects fiber size rather than number [19, 20]. Impor-
tantly, incubation of human myoblasts with myostatin
has been found to reduce Akt phosphorylation at residue
Ser473 by 50 % [14]. The reduction of Akt phosphory-
lation by myostatin might underlie its inhibiting effect
on muscle hypertrophy. Recently, researchers discovered
that this effect is mediated via the microRNA miR-486
[21]. miR-486 increases Akt phosphorylation, likely by
inhibiting phosphatase and tensin homolog (PTEN), a
protein which opposes the action of PI3K by dephospho-
rylating PIP3 to PIP2 [22]. Myostatin negatively regulates
the expression of miR-486 at the transcriptional level
and therefore inhibits Akt phosphorylation mediated by
PI3K.
After Akt is activated it phosphorylates several other
proteins. The best researched substrates of Akt are glyco-
gen synthase kinase 3β (GSK3β) [23], proline-rich Akt
substrate of 40 KDa (PRAS40) [24], tuberous sclerosis
Fig. 1 Regulation of mTORC1 by growth factors. Activation of the IR and IGF-1R leads to phosphorylation of the IRS which subsequently activate PI3K.
PI3K generates PIP3 which recruits PDK1 and Akt to the plasma membrane. Akt is then activated by PDK1 and mTORC2. Activated Akt then inhibits
several substrates, namely the TSC-TBC complex which functions as a negative regulator of mTORC1, GSK3β which degrades β-catenin, FoxO3a
which stimulates MuRF1 and MAFbx and PRAS40 which inhibits mTORC1. Akt activation is also induced by androgens, possibly by enhancing PI3K
activity and mediated by GPCR6A. Additionally, Akt activation is inhibited by activation of ActRII receptors through activation of Smad2 and Smad3
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complex 2 (TSC2) [25] and forkhead box class O (FoxO)
proteins [26]. Both TSC2 and PRAS40 act as negative
regulators of mTORC1. TSC2 forms a protein complex
with TSC1 and the recently discovered protein TBC1D7
[27]. When the TSC1-TSC2-TBC1D7 (TSC-TBC) com-
plex is formed, it inhibits mTORC1 activity bymeans of its
GTPase-activating protein (GAP) domain [27, 28]. GTP-
bound Rheb proteins (Rheb-GTP) activate mTORC1 at
the lysosomal membrane [29]. The mechanism for this
activation is currently unknown although interaction with
the mTOR kinase domain appears to be involved [29].
By virtue of its GAP domain, the TSC-TBC complex can
thus regulate the amount of Rheb-GTP and therefore
mTORC1 activity. Akt phosphorylates TSC2 at multi-
ple sites (Ser939, Ser981, Ser1130, Ser1132 and Thr1462)
in order to inhibit the GAP activity of the TSC-TBC
complex towards Rheb-GTP, possibly by dissociating the
complex from the lysosome [30]. Moreover, it should
be noted that the TSC-TBC complex has the highest
affinity for Rheb-GDP rather than Rheb-GTP [30]. This
might suggest a mechanism in which the complex acts
to prevent the exchange of GDP for GTP in order to
keep the Rheb proteins from reloading GTP. Akt further
acts by relieving mTORC1 of the inhibition imposed by
PRAS40. PRAS40 binds to the mTORC1 subunit Raptor,
thereby inhibiting its association with substrates. PRAS40
is phosphorylated at one threonine residue (Thr246)
and two serine residues (Ser181 and Ser221) [31]. The
threonine residue is phosphorylated by Akt, whereas
the serine residues appear to be phosphorylated by
mTORC1.
GSK3β is a negative regulator of the Wnt/β-catenin
signaling pathway as it forms a complex with other pro-
teins and phosphorylates β-catenin leading to degrada-
tion of the molecule [32]. Akt phosphorylates GSK3β ,
which inactivates the enzyme and thereby stimulates
Wnt/β-catenin signaling through removal of its inhibiton.
β-catenin seems to play an important role in skeletal
muscle hypertrophy by functioning as a transcription
factor [33] and inhibition of GSK3β stimulates hyper-
trophy in C2C12 myotubes [34]. The kinase has also
been found to inhibit mRNA translation by blocking
the GDP-GTP exhange of eIF2B [35] which is required
to form a functional ternary complex for translation
initiation [36].
Besides the regulation of anabolic processes through
inhibition of GSK3β , PRAS40 and TSC2 activity, Akt
is also closely involved in inhibiting protein break-
down by modulating the activity of the FoxO family of
proteins. FoxO proteins are key regulators of protein
breakdown modulating ubiquitin-proteasome, as well as
autophagy-lysosomal proteolytic pathways [37]. Espe-
cially the first seems important in muscle protein break-
down and two E3 ubiquitin ligases, muscle atrophy F-box
(MAFbx/atrogin-1) and muscle ring finger 1 (MuRF1)
[38, 39], appear to be the two main downstream effec-
tors of FoxO signaling affecting protein breakdown. FoxO
proteins are phosphorylated, and thereby inhibited, by
Akt [40].
Aside from the regulation of Akt by insulin and IGF-
I, some studies [41–46], but not all [47–50], suggest
androgens also increase Akt phosphorylation. The large
heterogeneity across these studies, such as differences
in experimental animal models, differences in the type
of androgen used as well as its dosage, timepoint of
measurement, among others, might explain why some
studies did not find an increase in Akt phosphoryla-
tion. Interestingly, one study examining the rapid effects
of testosterone in cultured rat myotubes directly impli-
cates the PI3K/Akt/mTORC1 pathway as a mediator of
androgens’ effect on contractile protein synthesis [46].
Basualto-Alarcón et al., incubated the myotubes with
testosterone (100 nM) and performed measurements
of total Akt and phosphorylated Akt (at Ser473) 1, 5,
15, 30 and 60 m after incubation. Measurements of
α-actin mRNA and protein were taken 6 and 12 h
after incubation with testosterone and both were sig-
nificantly increased, thus indicating an increase in con-
tractile protein synthesis. Indeed, the cross-sectional area
(CSA) was significantly increased after 12 h. Moreover,
Akt phosphorylation was increased 15 m after incuba-
tion. When the authors inhibited PI3K, Akt or mTOR
the effect on α-actin was blocked. As such, it appears
likely that androgens exert rapid effects by activation
of the PI3K/Akt/mTOR pathway. Given that PI3K oper-
ates at the cell membrane and that the effect on Akt
phosphorylation occured rapidly (after 15 m), it appears
highly likely that a cell membrane-localized receptor is
involved. Indeed, multiple lines of evidence implicate a
cell membrane-localized receptor in the rapid effects of
androgens [51]. The G-protein coupled receptor (GPCR)
GPRC6A has been shown to mediate a rapid signaling
response, including involvement of PI3K, to testosterone
[52]. In the experiment by Basualto-Alarcón et al., the
addition of the androgen receptor (AR) antagonist bicalu-
tamide blocked the increase in CSA, despite an increase in
α-actin protein level. This indicates crosstalk between the
intracellular AR and the PI3K pathway activated by testos-
terone. Strikingly, the intracellular AR has been shown
to interact with the p85α regulatory subunit of PI3K in
androgen-sensitive epithelial cells, enhancing its activ-
ity [53]. However, the addition of bicalutamide to these
androgen-sensitive epithelial cells blocked the androgen-
induced Akt phosphorylation. This is in contrast with the
experiment by Basualto-Alarcón et al., which showed that
inhibition of Akt phosphorylation blocked the increase in
α-actin protein level, whereas bicalutamide did not affect
α-actin protein level, thus suggesting that bicalutamide
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did not inhibit Akt phosphorylation in this experiment.
If bicalutamide also affected Akt phosphorylation in the
experiment by Basualto-Alarcón et al., this should there-
fore be observed in α-actin protein level, but it remained
unaltered by addition of bicalutamide. This difference
between both studies might be due to the differences in
cell lines and AR ligands used. Nevertheless, AR-PI3K
crosstalk might, partly, underlie the absence of an increase
in CSA with the addition of bicalutamide in the exper-
iment by Basualto-Alarcón et al., despite an increase in
α-actin. Additionally, activation of the PI3K/Akt path-
way can, in turn, regulate AR activity, since Akt has been
shown to post-translationally modify the AR by phospho-
rylation [54]. Further research might further elucidate the
mechanisms through which the cell membrane-localized
and intracellular AR regulate mTORC1 activity.
Regulation by energy status
The regulation of mTORC1 by energy status of the cell
is less well described than that of growth factors and
appears primarily mediated through the AMP-activated
kinase (AMPK). AMPK is a heterotrimeric protein com-
prising a combination of α, β and γ subunits. Cur-
rently there are two isoforms known of both the α (α1
and α2) and β (β1, β2) subunits. There are three iso-
forms known of the γ subunit (γ 1, γ 2, γ 3). The α-
subunit functions as the catalytic subunit of the complex,
whereas the other two subunits ’sense’ the energy sta-
tus of the cell. The β-subunit can interact with glycogen
[55] and the γ -subunit with the nucleotides adenosinet-
riphosphate (ATP), adenosinediphosphate (ADP) and
adenosinemonophosphate (AMP) [56]. The interaction
between glycogen and the β-subunit leads to allosteric
inhibition of AMPK activity, a decrease in glycogen will
therefore lead to relieve of this inhibition and thus acti-
vation of the complex. In sum, the β and γ subunits
allow the kinase to measure the energy status of the cell
as reflected by its glycogen content and ATP to ADP or
AMP ratio. A decrease in glycogen or the ATP to ADP
or AMP ratio signals a decrease in available energy to the
kinase and activates it. In general, activation of AMPK
promotes catabolic pathways in order to recover cellular
energy homeostasis and attenuates anabolic pathways to
preserve energy (Fig. 2) [56, 57].
Theoretically, the different isoforms of the subunits
allows for twelve unique combinations. However, to
date only three different combinations have been found
in human skeletal muscle: α2/β2/γ 1, α2/β2/γ 3 and
α1/β2/γ 1 [58]. The quantitative distribution of these
heterotrimeric proteins has been estimated at 15 %
α1/β2/γ 1, 65% α2/β2/γ 1 and 20 % α2/β2/γ 3. The three
heterotrimers show differential regulation and effects
[59]. The α2/β2/γ 3 heterotrimer is rapidly activated fol-
lowing physical activity, whereas the other two take far
longer to activate. Additionally, only the α1-containing
heterotrimer appears to attenuatemuscle growth, whereas
the α2-containing heterotrimers do not appear to do
so [60].
The antagonizing effect AMPK has on muscle growth
is mediated, atleast in part, by inhibiting mTORC1 activ-
ity. AMPK phosphorylates two residues (Thr1227 and
Ser1345) on TSC2 which are important for its activation
[61]. TSC2 then acts to inhibit mTORC1 by formation
of the TSC-TBC complex as described earlier. More-
over, Raptor, one of the proteins compromising mTORC1,
has also been found to be a substrate of AMPK [62].
Phosphorylation of Raptor at residues Ser722 and Ser792
likewise inhibits mTORC1 activity.
Fig. 2 Regulation of AMPK by energy status. The γ -subunit interacts with the nucleotides ATP, ADP and AMP. A high ATP to ADP and AMP ratio
inhibits AMPK, whereas a decrease in the ratio activates the kinase. Interaction of glycogen with the β-subunit allosterically inhibits AMPK activity.
Activated AMPK phosphorylates TSC2 at two residues (Thr1227 and Ser1345) which are important for its activation. Moreover, activated AMPK
phosphorylates Raptor at two residues (Ser722 and Ser792) which inhibits mTORC1 activity
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In sum, the antagonistic effect of AMPK on mTOR is
mediated through phosphorylation of TSC2 and Raptor.
Regulation by amino acids
It should come as no surprise that the availability of
the basic building blocks of protein control its synthe-
sis. When a cell is deprived of amino acids, mTOR can
be found throughout the cytoplasm, whereas addition of
amino acids rapidly localizes mTOR to the peri-nuclear
region of the cell, to large vesicular structures, or to
both [63]. The amino acid-induced locatization is simi-
lar to that of Rab7, a late endosome-/lysosome-associated
small GTPase. This suggests that amino acids might
stimulate mTORC1 activity by localizing it to lysoso-
mal surface where it can be activated by Rheb-GTP. The
Ragulator-Rag complex was found responsible for tar-
geting mTORC1 to the lysosomal surface [64]. At the
lysosomal surface, mTORC1 associates with Ras-related
GTPases (Rags). There are four different Rags: RagA,
RagB, RagC and RagD. RagA and RagB (RagA/B) bind to
RagC and RagD (RagC/D) to form heterodimeric pairs.
Rags, in turn, associate with the protein complex Rag-
ulator which is anchored in the lysosomal membrane.
The interaction of Rags with mTORC1 is dependent
on their guaninenucleotide binding state. In an amino
acid-deprived cell, the RagA/B are bound to GDP, and
the RagC/D are bound to GTP. The addition of amino
acids induce a nucleotide exchange favoring the GTP
bound state of RagA/B and the GDP bound state of
RagC/D. The Ragulator, anchored in the lyosomal mem-
brane, associates with Rags, therefore localizing them
to the lysosomal membrane. Importantly, the Ragula-
tor functions as a guanine nucleotide exchange factor
(GEF) for RagA/B [65], thereby facilitating the exchange
of GDP bound RagA/B for GTP bound RagA/B (the
active form). The GEF activity of Ragulator is regulated
by v-ATPase [65]. v-ATPase consumes ATP in order to
pump hydrogens up their concentration gradient into the
lysosome in order to maintain its acidic environment.
Ragulator is associated with v-ATPase and amino acids
induce a conformational change to the protein which
then acts to activate Ragulator’s GEF activity. As of yet
it is unclear how amino acids induce this conformational
change, but the signal appears to originate from inside
the lysosome due to accumulation of amino acids in its
lumen (Fig. 3) [66].
Whereas Ragulator acts as a GEF for RagA/B, the
GAP activity towards Rags (GATOR1) complex func-
tions as a GAP towards RagA/B [67]. The GATOR1
complex thus exchanges the GTP for GDP of RagA/B,
leading to deactivation of the Rags and subsequently inhi-
bition of mTORC1. Another protein complex dubbed
GATOR2 is responsible for inhibiting GATOR1 activity
[67] and therefore relieves mTORC1 from its inhibition.
The inhibiting effect of GATOR2 on GATOR1 is mediated
by Sestrin proteins in response to amino acids [68]. How-
ever, it is unknown how GATOR2 mediates its inhibiting
effect and how amino acids regulate the complex.
Lastly, there is evidence that the guanine nucleotide
binding state of RagC/D is regulated by leucyl tRNA-
synthetase (LRS), the enzyme responsible for loading
tRNA with leucine. The enzyme acts as a GAP for RagD
GTPase, in a leucine depedent manner [69]. However,
a later study found that purified LRS did not act as a
GAP for any of the Rags [70]. Instead the authors propose
that folliculin tumor suppressor (FLCN) and its binding
partners act as Rag-interacting proteins with GAP activ-
ity for RagC/D, leading to mTORC1 activation. Moreover,
leucine specifically appears to regulate mTORC1 through
Sestrin2 [71].
Fig. 3 Regulation of mTORC1 by amino acids. a The Rags are found in their inactive state under low amino acid conditions and therefore are unable
to recruit mTORC1 to the lysosomal membrane for activation by Rheb-GTP. Ragulator and v-ATPase are in their inactive state, whereas GATOR1
exerts GAP-activity towards RagA/B, ensuring an inactive state of these Rags. b An increase in the amino acid concentration triggers a
conformational change in v-ATPase and Ragulator, which initiates GEF activity towards RagA/B of the latter. FLCN and its binding partners exhibit
GAP activity towards RagC/D and thereby activating them as well. Additionally, GATOR1 its GAP activity is inhibited due to inhibition of GATOR2.
These actions lead to the active heterodimer of GTP-bound RagA/B and GDP-bound RagC/D, which then recruit mTORC1 to the lysosomal surface
where it can be activated by Rheb-GTP. Figure based on [99]
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Regulation bymechanical stimuli
It is well known that physical activity, resistance exercise
in particular, increases skeletal muscle mass in healthy
persons under most conditions. Currently, two impor-
tant mechanisms have been identified which regulate
mTORC1 by mechanical stimuli. One of these mech-
anisms shows close resemblance with the PI3K/Akt-
pathway in that it leads to dissociation of TSC2 from
the lysosomal membrane [72]. Eccentric contractions
lead to phosphorylation of TSC2 which leads to the
dissociation observed. Since Rheb-GTP, the target of
the TSC-TBC complex its GAP activity, is located at
the lysosomal membrane, mechanical stimuli effectively
prevents the GTP/GDP-exchange. Moreover, mechanical
stimuli increase the levels of mTORC1 at the lysosomal
membrane, further supporting its activation [72]. The
mechanism for this remains uncertain (Fig. 4).
Secondly, mechanical stimuli regulate mTORC1 by reg-
ulating levels of phosphatidic acid (PA), a diacylglycerol
phospholipid which has been found to directly activate
mTORC1 [73]. A twofold effect mediates the stimulating
effect of PA on mTORC1: i) displacing the endogeneous
mTORC1 inhibitor FK506 binding protein 38 (FKBP38)
through competitive inhibition, ii) allosteric activation of
mTORC1.
The [PA] is regulated by five classes of enzymes [74].
Three are responsible for the synthesis of PA and two
regulate its degradation. A delicate balance between
the activities of these enzymes determines cellular PA
levels. Glycerol-3-phosphate (G3P), phosphatidylcholine
(PC) and diacylglycerol (DAG) are precursors for the
biosynthesis of PA. G3P is acetylated twice in order to
produce PA. First glycerol-3-phosphate acyltransferase
(GPAT) catalyzes the first acetylation reaction, after which
Fig. 4 PA can be synthesized from G3P, PC and DAG. G3P is
acetylated twice, requiring fatty-acyl-CoA for its acetylation. First it is
acetylated by GPAT and then by LPAAT. PLD is hydrolyzed by PLD to
produce PA and DAG is phosphorylated by DGK to produce PA. DAG
is derived from triacylglycerols and phosphatidylinositol. PA phosphatase
(PA P’tase) is responsible for dephosphorylation of PA to DAG. Various
CDP-diacylglycerol synthases produce CDP-diacylglycerol from PA.
Figure based on [74]
lysophosphatidic acid acyltransferase (LPAAT) catalyzes
the second. PC is hydrolyzed in order to produce PA. This
reaction is catalyzed by phospholipase D (PLD). For long
it had been assumed PLD was crucial in mediating the
mechanical stimuli-induced increase in PA. This assump-
tion was mainly based on experiments which applied
the PLD inhibitor 1-butanol, which effectively inhibited
mTORC1 activity in several experiments [75]. However,
later it was found that not all biological activity induced by
1-butanol could be attributed to its PLD inhibiting effect.
Moreover, earlier findings already reported that PLD
activity induced by mechanical stimuli poorly correlated
with the cellular increase of PA [76]. Recent evidence sug-
gests that the mechanical stimuli-induced increase of PA
might be attributed to an increased synthesis from DAG
rather than PC. PA is produced from DAG by phospho-
rylation catalyzed by diacylglycerolkinases (DGK). Many
DGKs have been identified and it appears the ζ -isoform is
primarily responsible for the mechanical stimuli-induced
increase of PA [77].
The regulation of the enzymes responsible for degrada-
tion of PA are currently poorly understood.
Sports supplements andmTORC1 signaling
In 2011, Kunkel et al. performed an elegant study to
identify a compound which might help against skeletal
muscle atrophy [78]. The authors screened for changes
in mRNA expression in both human and rodent skeletal
muscle during fasting and spinal cord injury. Both fasting
and spinal cord injury involve dramatic muscle atrophy
over time and this effect is driven by changes in mus-
cle gene expression. The authors therefore hypothesized
that pharmacologic compounds with opposite effects on
gene expression might inhibit skeletal muscle atrophy. By
querying the Connectivity Map [79] with the data they
gathered, they identified ursolic acid as a potential phar-
macologic compound which might inhibit skeletal muscle
atrophy. After identification of the compound they con-
tinued to test its effects in mice and found it to reduce
muscle atrophy and stimulate muscle hypertrophy. Inter-
estingly, IGF-I mRNA was upregulated in skeletal mus-
cle of the mice treated with ursolic acid. Moreover, Akt
phosphorylation was also increased. The researchers also
evaluated the effect of C2C12 myoblasts incubated with
ursolic acid and found that, on its own, it did not increase
Akt phosphorylation. However, in the presence of IGF-I
ursolic acid did increase Akt phosphorylation. Similarly,
ursolic acid alone did not upregulate S6K1 phosphoryla-
tion, but it did enhance IGF-I- and insulin-mediated S6K1
phosphorylation. Later research confirmed these findings
and found that ursolic acid stimulates mTORC1 signal-
ing in rat skeletal muscle [80]. This was evidenced by
an increase in phosphorylation of Akt (at Thr308, but
not Ser473), PRAS40 and S6K1 after resistance exercise.
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A recent clinical study also found an improvement in
body composition and strength in sixteen Korean men
with over 3 years resistance exercise experience who were
supplemented ursolic acid compared to placebo [81].
Some evidence suggests that the popular ergogenic
aid creatine might also stimulate mTORC1 signaling.
In a double-blind placebo-controlled study, participants
received either placebo or creatine for 5 days [82]. Mus-
cle biopsies were then taken at rest, immediately after
exercise, 24 and 72 h later. The phosphorylation of Akt
at Ser473 and Thr308 were determined, as well as the
phosphorylation of 4E-BP1 and S6K1. Surprisingly, cre-
atine supplementation decreased Akt phosphorylation at
Thr308 in rest, whereas it was unaffected immediately,
24 and 72 h post-exercise. Akt phosphorylation at Ser473
was unaffected at all time points. Similar results were
obtained for 4E-BP1 and S6K1 phosphorylation: 4E-BP1
phosphorylation showed a decrease 24 h after training,
while it remained unaffected at all other time points
and S6K1 phosphorylation remained unchanged at all
time points. Nevertheless, MHCIIA mRNA expression
showed an increase immediately after exercise andMHC1
mRNA expression showed an increase during rest after
creatine supplementation compared to placebo. However,
another study with a similar experimental design found
an increase in phosphorylated 4E-BP1 24 h after exercise
in the creatine group compared to placebo, but found no
difference in phosphorylated S6K1 between both groups
[83]. Again, no difference was found in phosphorylated
4E-BP1 and S6K1 3 h post-exercise. Notably, an increase
in IGF-I mRNA expression was also observed 24 h post-
exercise in the creatine group compared to placebo. These
results suggest that creatine might activate mTORC1 by
increasing IGF-I activity at rest, but does not further
potentiate mTORC1 signaling in the hours after exercise.
Interestingly, a clinical study also found that creatine sup-
plementation amplified the resistance exercise-induced
decrease in serum myostatin [84]. Although no markers
of the mTORC1 pathway were measured in this study,
it might be that a decrease in serum myostatin might
enhance Akt phosphorylation and thus mTORC1 activity.
The mTORC1 signaling pathway is also thought to be
involved in the anabolic effects of the leucine metabo-
lite β-hydroxyβ-methylbutyrate (HMB) [85, 86]. In rats
fed HMB, mTOR protein expression increased signifi-
cantly compared to treatment with saline [87]. More-
over, phosphorylated S6K1 also increased significantly in
the HMB treated rats compared to the control group.
Similar results were obtained in an in vitro experiment
[88]. C2C12 myoblasts were incubated with proteolysis-
inducing factor (PIF, a protein which stimulates pro-
teolysis and inhibits protein synthesis) and addition of
HMB increased S6K1 phosphorylation. Notably, in the rat
study no differences were found in Akt phosphorylation
between both groups. However, another in vivo exper-
iment did find an increase in phosphorylated Akt in
differentiated C2C12 myoblasts 10 and 30 m after incuba-
tion with HMB, as well as an increase in phosphorylated
mTOR 30 m after incubation [89]. These results might
seem conflicting, but the measurements in the rat study
were taken 15 h to 18 h after HMB supplementation.
Thus it might be that the activation of Akt/mTORC1 sig-
naling was short-lived and was therefore missed in the
rat study. Interestingly, another leucine metabolite, α-
hydroxy-isocaproic acid (HICA), has shown to increase
whole lean body mass when compared to placebo in a
small sample of soccer players [90]. Rats fed HICA and
recovering from hindlimb immobilization also showed a
sustained increase in protein synthesis and phosphoryla-
tion of S6K1 and 4E-BP1 after 14 days when compared
to placebo and leucine [91]. Further research might fur-
ther clarify the role of mTORC1 signaling in the anabolic
effects of these leucine metabolites.
Trimethylglycine (TMG), amethyl derivate of the amino
acid glycine and also known as betaine, was recently
shown to improve body composition when supplemented
to trained athletes [92]. TMG is hypothesized to work as
an ergogenic aid by functioning as both an osmolyte as
well as a methyl donor in cells [93]. In a small double-
blinded crossover trial, participants underwent 2 weeks of
supplementation with either TMG or placebo [94]. Before
and after the 2-week period, participants performed an
acute exercise session. Both before the supplementation
period, as well as 10 m before and after exercise, mus-
cle biopsies were taken from the vastus lateralis muscle.
Total Akt protein content was significantly increased in
the TMG group compared to placebo. There was no dif-
ference in phosphorylated Akt and S6K1 in rest, but there
was a decrease in phosphorylated Akt and S6K1 after
the acute exercise session in the placebo group which
did not occur in the TMG group. AMPK phosphory-
lation at Thr172 was also measured, but there was no
difference between both groups. Notably, an increase in
circulating growth hormone (GH) and IGF-I concentra-
tions was observed in the TMG group, but not in the
placebo group. This makes it appealing to speculate that
the increase in circulatory GH and IGF-I underlies the
effect of TMG on Akt. However, it should be taken into
account that local GH and IGF-I, rather than circula-
tory, appear to affect skeletal muscle hypertrophy [95].
Nevertheless, an in vitro experiment in C2C12 myoblasts
showed an increase in IGF-1 receptor protein expression
after incubation with TMG [96]. An increase in Akt and
myosin heavy chain protein content was also observed.
Taken together these observations suggest that TMG acti-
vates the IGF-I/Akt/mTORC1 pathway.
A recent study also showed that PA supplementa-
tion activated mTORC1 and improved responses in
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skeletal muscle hypertrophy, lean body mass, and maxi-
mal strength to resistance exercise [97]. A sample of 28
resistance trained men received either PA or placebo and
took part in an 8 week periodized resistance training pro-
gram. The PA group showed a larger increase in lean
body mass than the placebo group and also the CSA of
the rectus femoris muscle showed a larger increase in the
PA group than the placebo group. The authors also per-
formed an in vitro experiment assessing phosphorylation
of S6K1 in C2C12myoblasts after incubation with two dif-
ferent sources of PA (egg and soy). While both showed a
large increase in phosphorylation of S6K1, the soy-derived
PA showed the largest increase. As the authors note, the
difference might be due to soy and egg derived PA hav-
ing varying degrees of unsaturated and saturated fatty acid
chains which influence its action. A later study carried
out both an in vivo and in vitro experiment to exam-
ine the effects of PA on anabolic signaling [98]. In the
in vivo experiment, male Wister rats received either tap
water (CON), PA (PA), whey protein concentrate (WPC)
or PA + WPC (PA+WPC) after an overnight fast. Sam-
ples were taken after 3 h. Ribosomal protein S6 (rpS6)
phosphorylation was increased in the PA and PA+WPC
groups compared to the CON group, whereas it was
not increased in the WPC group. S6K1 phosphorylation
was also only significantly increased compared to con-
trol in the PA+WPC group. However, while PA showed an
increase in MPS compared to CON, the largest increase
in MPS was observed in the WPC group. There was no
synergistic effect of PA+WPC in MPS when compared to
WPC alone. The authors therefore speculate that com-
bined PA andWPCmight alter mTOR pathway activation
dynamics, thus shifting MPS levels to the left or right of
the sampling point or that PA might interfere with WPC-
induced increases in MPS. Future research might clarify
this matter. Their in vitro experiment in C2C12 myoblasts
confirmed that PA increased MPS and mTOR signaling.
Conclusions
In the past few years our knowledge of mTORC1 regula-
tion in skeletal muscle has increased tremendously. This
review therefore attempted to provide a brief and up-to-
date narrative on its regulation. Energy intake, protein
intake, mechanical stumuli, as well as growth factors, have
been shown to regulate the mTORC1 complex. All these
elements provide signals to muscle cells which are then
sensed, transduced and integrated which leads to changes
in cellular functions. Ultimately, these signals are sensed
by proteins such as cell surface receptors or intracellular
kinases. For example, the IR senses the concentration of
insulin outside the cell and relays this signal through the
PI3K/Akt/mTORC1 pathway, whereas energy availabil-
ity is directly relayed through AMPK by the nucleotides
ATP, ADP and AMP as well as stored glycogen. Finally,
these signals are integrated by the cell in order to respond
accordingly by changing cellular functions such as pro-
tein synthesis and protein breakdown. mTORC1 plays a
pivotal role in integrating several of these signals such as
growth factors, energy status, amino acids availability and
mechanical stumuli. All these signals together affect the
cellular response. Sports supplements might benefit the
athlete in optimizing these signals, in addition to resis-
tance exercise training, to maximize muscle hypertrophy.
While ultimately clinical trials are required to properly
evaluate their effects, they are expensive and sometimes
difficult to carry out. For example, it can be challenging
to find enough participants which conform the criteria of
interest (e.g. young adults with several years of weightlift-
ing experience) to yield enough statistical power. Addi-
tionally, strictly controlling all variables, such as dietary
intake, can be hard. This is of special concern in studies
of several weeks or months of duration. Insights in the
mechanistic features of sports supplements might there-
fore aid clinical trials by providing hypothesizes under
which conditions supplements might work best, as well
as which combinations of supplements might provide
additive effects. Additionally, it might aid in discovering
new supplements of interest. The increasing knowledge
of mTORC1 regulation therefore helps to refine these
matters.
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